

---

**Product Data Sheet**

---

Product Name: Brepocitinib (PF-06700841)

Cat. No.: GC25168

**Chemical Properties**

Cas. No. 1883299-62-4

Formula C<sub>18</sub>H<sub>21</sub>F<sub>2</sub>N<sub>7</sub>O

M.Wt 389.4

Solubility DMSO: 78 mg/mL (200.31 mM); Water: Insoluble; Ethanol:  
78 mg/mL (200.31 mM)Storage Store at  
-20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC<sub>50</sub>s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.

The pharmacokinetics of PF-06700841 are studied in Sprague-Dawley rats following intravenous and oral administration (1 and 3 mg/kg respectively) of the tosylate salt, where the compound shows a plasma clearance of 31 mL/min/kg, a volume of distribution of 2.0 L/kg, and oral bioavailability of 83%. Following the 3 mg/kg oral dose, the C<sub>max</sub> is 774 ng/mL and the AUC<sub>∞</sub> is 1340 ng.h/mL. The high oral bioavailability indicates high absorption from the gut, consistent with its in vitro passive permeability properties and high solubility[1].

[1] Fensome A, et al. J Med Chem. 2018, 61(19):8597-8612.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA